**Name of Journal: *World Journal of Clinical Oncology***

**ESPS Manuscript NO: 21494**

**Manuscript Type: Review**

**Role of the microbiome in non-gastrointestinal cancers**

Pevsner-Fischer M *et al.* Microbiome in non-gastrointestinal cancers

**Meirav Pevsner-Fischer, Timur Tuganbaev, Mariska Meijer, Sheng-Hong Zhang, Zhi-Rong Zeng, Min-Hu Chen, Eran Elinav**

**Meirav Pevsner-Fischer, Timur Tuganbaev, Eran Elinav,** Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel

**Mariska Meijer,** Leiden University Medical Centre, Leiden University, 2300 RC Leiden, the Netherlands

**Sheng-Hong Zhang, Zhi-Rong Zeng, Min-Hu Chen,**Division of Gastroenterology, the First Affiliated Hospital, Sun Yat-sen University, 51008 Guangzhou, Guangdong Province, China

**Author contributions:** All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.

**Conflict-of-interest** **statement:** No conflicts of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Eran Elinav, MD, PhD,** Department of Immunology, Weizmann Institute of Science, 100 Herzl Street, Rehovot 7610001, Israel. eran.elinav@weizmann.ac.il

**Telephone:** +972-8-9344014

**Received:** July 15, 2015

**Peer-review started:** July 17, 2015

**First decision:** November 3, 2015

**Revised:** January 24, 2016

**Accepted:** February 23, 2016

**Article in press:**

**Published online:**

**Abstract**

“The forgotten organ”, the human microbiome, comprises a community of microorganisms that colonizes various sites of the human body. Through coevolution of bacteria, archaea and fungi with the human host over thousands of years, a complex host-microbiome relationship emerged in which many functions, including metabolism and immune responses, became codependent. This coupling becomes evident when disruption in the microbiome composition, termed dysbiosis, is mirrored by the development of pathologies in the host. Among the most serious consequences of dysbiosis, is the development of cancer. As many as 20% of total cancers worldwide are caused by a microbial agent. To date, a vast majority of microbiome–cancer studies focus solely on the microbiome of the large intestine and the development of gastrointestinal cancers. Here, we will review the available evidence implicating microbiome involvement in the development and progression of non-gastrointestinal cancers, while distinguishing between viral and bacterial drivers of cancer, as well as “local” and “systemic”, “cancer-stimulating” and “cancer-suppressing” effects of the microbiome. Developing a system-wide approach to cancer-microbiome studies will be crucial in understanding how microbiome influences carcinogenesis, and may enable to employ microbiome-targeting approaches as part of cancer treatment.

**Key words:** Microbiome; Non-gastrointestinal cancers; Carcinogenesis; Dysbiosis; Microbial agent

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** “The forgotten organ”, the human microbiome, comprises a community of microorganisms that colonizes various sites of the human body. A complex host-microbiome relationship has emerged in which many functions became codependent. This coupling becomes evident when disruption in the microbiome composition, termed dysbiosis, is mirrored by the development of pathologies in the host. Among the most serious consequences of dysbiosis, is the development of cancer. As many as 20% of total cancers worldwide are caused by a microbial agent. Here, we will review the available evidence implicating microbiome involvement in the development and progression of non-gastrointestinal cancers. Developing a system-wide approach to cancer-microbiome studies will be crucial in understanding how microbiome influences carcinogenesis, and may enable to employ microbiome-targeting approaches as part of cancer treatment.

Pevsner-Fischer M, Tuganbaev T, Meijer M, Zhang SH, Zeng ZR, Chen MH, Elinav E. Role of the microbiome in non-gastrointestinal cancers. *World J Clin Oncol* 2016; In press

**INTRODUCTION**

Bacteria, viruses, archaea and fungi coevolved with the human body for thousands of years. This resulted in diverse and extensive host-microbiome interactions, which influence multiple host physiological processes, including metabolism and the function of the immune system[1]. Disruption of the microbial community, termed dysbiosis, is suggested to constitute a major risk factor for an increasing array of diseases including metabolic syndrome and immune disorders as well as several forms of cancer.

Carcinogenesis is a process inflicted and influenced by many mechanisms. However, up to 20% of the cancers worldwide are believed to be caused or modulated by a microbial agent[2,3]. Of the various involved microorganisms, viruses are best studied for their role in carcinogenesis. Therefore, multiple mechanisms through which viruses promote development of tumors have been deciphered. The roles of archaea and fungal members of microbiome in cancer formation are much less studied, while only recently studies emerged focusing on bacterial involvement in cancer formation and progression.

This review will provide some conceptual examples of how different organ-specific microbiomes may modulate the carcinogenic processes through involvement of specific members or, alternatively, through changes observed in the microbial community as a whole (summarized in Table 1). An early example of an individual bacterial member that contributes to carcinogenesis is *Helicobacter pylori* (*H. pylori*). *H. pylori* colonizes the gastric mucosa in 50% of humans and causes cancer in 1%-3% of colonized individuals. It thus is recognized by the International Agency for Research on Cancer (IARC) as a bone-fide carcinogen[4]. However, further experiments in germ-free mice showed that infection by *H. pylori* alone was not sufficient to promote neoplastic transformation. Mice mono-associated with the bacteria developed gastritis and subsequent neoplasia at a much slower rate than their fully colonized counterparts, suggests that *H. pylori* may require cooperation by other commensal microbiota members. In other cases an entire dysbiotic microbiome community was suggested to drive tumor development. One such example is colorectal cancer (CRC) that is transmissible by dysbiotic microbiota[5,6]. As such, germ-free mice are partially protected from disease, and treatment with broad-spectrum antibiotics ameliorates cancer development. Identifying the pathogenic bacterial “drivers” of cancer in these cases and differentiating them from secondary microbial alterations remains a major challenge to the field.

Most studies have focused on the effect of the microbiota on gastrointestinal cancers and these are reviewed in detail elsewhere[7-11]. In this review, we will discuss research into the carcinogenic properties of microbial agents in the non-gastrointestinal organs. We review these associations per body-site, and highlight the substantial effect microbial involvement may have on all stages of cancer development in the skin, breast, urogenital tract, lung, liver and pancreas.

***Skin***

The human skin is the largest organ in the body and hosts a complex and heterogeneous microbiota. Until recently, the studies of the skin microbiota focused on bacteria, using culture-based assays. However, it has recently been appreciated that the skin is inhabited by a massive, unculturable bacterial ecosystem, as well as by fungi and viruses[12-14]. Together, these comprise the skin microbiome, which may have diverse effects on a multitude of skin-specific physiological and pathophysiological processes, including ones that promote the development of skin cancer.

**VIRAL INVOLVEMENT IN SKIN CANCER**

The skin virome has rarely been investigated, in part because most skin-associated viruses are not culturable and do not display consensus sequences that can be used for high throughput next generation sequencing techniques[15]. Several viruses are known to inhabit the healthy skin, but can also induce malignant transformation.

***The papilloma virus family***

Papilloma viruses (PVs) infect undifferentiated keratinocytes in the basal layer of the stratified squamous epithelia, and in the cutaneous and the mucosal levels. Oncogenic PVs, including the human papilloma virus (HPV-16), are responsible for nearly all cases of cervical and anal cancer[16]. PVs are commonly part of the skin and mucosal microbiota of healthy individuals, suggesting commensalism or mutualism between PVs and their host cells[17]. Moreover, the majority of HPV infections are subclinical and do not cause any physical lesions[17]. However, in some cases chronic inoculation is established through immune escape mechanisms, and a low yet persistent amount of virions in produced. The oncogenic features that allow the virus to induce cell transformation are dependent on the virus’s E5, E6 and E7 oncogenes, which are exclusively present in oncogenic PVs. The E6 protein in oncogenic PVs is able to induce degradation of the p53 cellular protein, thus promoting uncontrolled cell growth. The E5 protein allows for evasion of the host’s immune surveillance and decreases the dependence of infected cells on growth factors. Finally, the E7 oncoprotein binds to the tumorsuppressive pRb, dissociating the transcription factor E2F from the pRb/E2F complex. The process induced by these three oncoproteins is slow, with progression from precursor lesions to invasive cancer usually requiring more than a decade[16].

More recently, another HPV member was found to be associated with an unusual form of skin cancer called Merkel cell carcinoma (MCC)[18], concisely reviewed in[19]. The Merkel cell polyomavirus (MCPyV) causes a rare but aggressive form of [skin cancer](http://en.wikipedia.org/wiki/Skin_cancer) and is present in about 80% of MCC tumor specimens. The MCPyV genome was shown to integrate into the cellular DNA of some MCC tumors and their metastases. A majority of MCC tumors also display constitutive expression of the MCPyV large T-antigen oncoprotein[20]. This suggests involvement of MCPyV in the oncogenesis of MCC.

**BACTERIAL INVOLVEMENT IN SKIN CANCER**

The skin microbiome contains an entrenched bacterial population, forming a microbiome that features a high spatial and temporal stability[21-24]. The skin contains different skin microenvironments, defined by sebaceous, moist and dry areas and by the different follicle densities[25]. The cutaneous microbiome consists predominantly of 4 bacterial phyla; actinobacteria, firmicutes, proteobacteria and bacteroidetes and six genera, propionibacterium, corynebacterium, staphylococcus, streptococcus and acinetobacter[23,26].

Several studies link commensal skin bacteria to malignant transformation. In one example, antibiotic-treated mice showed an increased susceptibility to B16/F10 melanoma, as well as Lewis lung carcinoma (LLC), and exhibited a shortened mean survival time, suggesting a protective role of the skin microbiome in cancer development in these models. In contrast, another experimental setting suggested that an intact commensal bacterial population, and specifically flagellated bacteria, may be required for malignant transformation in the murine skin[27]. In this context, toll-like receptor (TLR) 5 and its ligand flagellin linked between chronic inflammation, tissue damage and skin cancer. In the model described, bone-marrow (BM) chimeras lacking MyD88 and TLR5 in the hematopoietic cells exhibited protection against a chemical model of wound-induced tumor formation. When mice were treated with a broad-spectrum antibiotic regimen, the skin bacterial load was decreased and wound-induced tumor formation and tumor size were substantially reduced. Topical application of flagellin onto wounds increased tumor incidence in a dose-dependent manner and delayed wound closure. This indicates that MyD88 and TLR-5 signaling on radiosensitive leukocytes is required for tumor formation. Together, these examples suggest that the skin bacterial microbiome can play either a protective or a harmful role in cancerogenesis, depending on the physiological context and microbial composition.

***Breast***

Breast cancer is the second leading cause of cancer-related deaths in women: one in eight women develop the malignancy in their lifetime[28]. Despite considerable and significant progress has been achieved in breast cancer research, in most cases it’s etiology remains unknown[29]. Mammary glands are colonized by a distinct microbiota[30,31],but the role of microbial involvement in breast cancer remains at its infancy.

**VIRAL INVOLVEMENT IN BREAST CANCER**

Until recently, most studies looking into microbial modulation of breast cancer have been focused on specific viruses. The results, however, remain inconclusive. While HPV infection has been reported by some groups to be associated with breast cancer development[32-34], others have failed to find such correlation[35,36]. Some groups have reported that up to 50% of breast tumors to be EBV-positive[37-40], while others have been unable to detect the virus in breast tumors altogether[41,42]. Therefore, additional studies are needed to clarify the potential contribution of viral infections in breast carcinogenesis, and its modulatory mechanisms of activity.

**BACTERIAL INVOLVEMENT IN BREAST CANCER**

In parallel to viral infections, a number of studies suggest a link between bacterial infections and breast cancer. Involvement of the commensal microbiome was first suggested in a study in which injections of a carcinogen (DMAB) in various body sites of germ free rats resulted in a significantly lower cancer burden in the breast tissue and colon, but not in the skin, as compared to conventionalized rats[43]. Of note, this study did not delineate whether the observed effects were linked to the local breast microbiome, or to distal microbial communities such as that of the gut. More recent studies have sought to clarify this issue. Xuan *et al*[31] surveyed the microbiota in tumors or normal adjacent tissues from 20 estrogen receptor (ER)-positive breast cancer patients as well as in tissue from healthy donors. This study indicated that there is a 10-fold decrease in the absolute numbers of bacteria between cancer and control tissues. Moreover, the authors observed changes in the compositional abundance of bacterial species in tumor compared to control tissues. While the genus *Sphingomonas* was found to be more abundant in normal tissues, the tumor tissue hosted *Sphingomonas yanoikuyae* in increased numbers*.* Other members of the skin microbiome, such *Staphylococcus* and *Corynebacterium*, did not vary significantly between normal and tumor tissues. Nonetheless, these data suggest that mammary tumors bear a different microbial composition than the normal tissue. Significant microbial-associated effects on tumor progression are supported by a recent study, which showed an accelerated mammary malignant progression in TLR5-responsive mice. In this model, malignant progression of mammary tissue in p53-ablated and oncogenic K-ras-activated mice was measured on the background of TLR5 deficient mice[44]. Absence of TLR5 signaling in these mice resulted in a divergent microbial composition and reduced tumor progression. In TLR5 proficient mice, on the other hand, microbial signaling through TLR5 increased IL-6 secretion and the number of ãä T cells as well as tumor growth. Thus, the commensal microbiome was suggested to be able to induce tumor-promoting inflammation in a TLR5 dependent manner.

While the above studies focuses on the whole microbiome composition and not on specific microbial “drivers” or “modulators” of cancer, a study by Lakritz Jr *et al*[30] implicated a specific bacterium, *Helicobacter hepaticus* (*H. hepaticus*), in the progression of mammary malignancy. In this report, mice with a predisposition for breast cancer were infected with *H. hepaticus*. Compared to non-infected controls, infected mice showed increased mammary tumor burden characterized by extensive neutrophil infiltration. Depletion of neutrophils entirely inhibited tumor development[30]. Together, these data suggest that both the whole microbiome composition as well as specific bacteria can contribute to breast tumor progression by promoting inflammation, and that they can do so *via* multiple pathways.

***Urogenital tract***

Urogenital cancers include cervical, renal, bladder and ovarian carcinomas. Very few studies focusing on the roles of the microbiota in urogenital tract tumors have been published to date (reviewed in[45]). Nonetheless, there is some emerging evidence towards the possibility that chronic viral infections may promote the development of renal cell carcinoma and bladder cancer.

**CERVICAL CANCER**

The most frequently occurring and the best studied of cancers of the female urogenital tract is cervical cancer. The most highly associated risk factor for cervical cancer is viral infection by the HPV family. Mucosal HPV serotypes infect the basal epithelial cells of the anogenital mucosa *via* micro-abrasions in the epithelial lining[46]. Vulval, vaginal, penile, cervical, and anorectal areas are affected. Cervical and anal squamous cell carcinoma develop at sites of squamous metaplasia; cervicovaginal and anorectal squamous columnar junctions are therefore especially vulnerable to HPV infection leading to malignant transformation[47]. Although data are limited, antibodies developed during natural infection do not seem to offer full protection against reinfection, possibly because of low or waning titers of the virus[48,49]. By contrast, the available prophylactic HPV vaccines induce high concentrations of neutralizing antibodies - at least two-log scale higher as compared to natural infection-induced concentrations, leading to a better immune memory[50,51]. The efficacy of the anti-HPV vaccine in cervical intraepithelial neoplasia (CIN2) associated with HPV 16 & 18 in women naive for infection is high: 93% (95%CI: 79.9-98.3) for the bivalent vaccine (HPV 16/18) after 35 mo of follow-up and 98% (95%CI: 93.3-99.8) for the quadrivalent vaccine (HPV 6/11/16/18) after 42 mo of follow-up[52-54].

**VAGINAL CANCER**

The vagina harbors a unique microbiota that serves as an important line of defense against pathogens, including sexually transmitted infections (STIs)[55]. The dominant members of the vaginal microbiome *Lactobacillus spp*. were shown to provide broad-spectrum protection from pathogens through their production of lactic acid[56], bacteriocins (bactericidal proteinaceous molecules)[57], antagonistic bacteriocin-like substances[58], and biosurfactants[59], that can adhere to mucus, a component of the barriers against pathogens[60] and disrupt biofilms[61]. Disruption of the protective microbiota configuration, termed bacterial vaginosis (BV) was shown in numerous studies to correlate with cervical cancer-inducing HPV infections[62-69]. BV affects one in three United States women[70] and is characterized by decrease in protective *Lactobacillus spp*., increased specie richness, and elevated numbers of anaerobic bacteria, including species of *Gardnerella, Prevotella,* and *Clostridiales*[71].

While numerous association studies showed a strong association between dysbiotic disruption of vaginal microbiota (BV) and HPV infections, the mechanistic link between the two events is yet to be explored.

**OVARIAN CANCER**

Chronic inflammation was previously suggested to be involved with the pathogenesis of Ovarian carcinogenesis[72], yet this evidence remains sparse. Specific pathogens suggested to be indirectly associated with human ovarian cancer include Chlamydial HSP60-1 IgG and *M. genitalium*, with IgG antibodies specific to these bacteria suggested to be associated with epithelial ovarian tumors in some patient subsets[73]. Possible involvement of impaired host-microbiome interactions in ovarian cancer was suggested from a study utilizing TLR-5 deficient mice that feature a dysbiotic microbiome configuration. These mice showed increased survival rates compare to WT controls when injected with syngenic ID8 ovarian tumor cells[44]. In addition, ovarian tumors of patients who were heterozygous for the dominant TLR5R392X polymorphism showed negligible induction of IL-8 transcript levels but significantly higher IL-17A transcript levels in response to flagellin as compared to control population. Furthermore, the proportion of long-term survivors was significantly higher among TLR5R392X carriers, all suggesting that host TLR5 microbe interactions may play a role in ovarian tumor pathogenesis[44].

**BLADDER CANCER**

Until recently, the healthy urinary tract was considered sterile and bacterial presence in the urine of patients identified *via* culture-based methods was considered a sign of a urinary tract infection (UTI)[45,74]. In recent years, however, the emergence of next generation sequencing of the microbiome has established the presence of a urinal microbiome in the healthy humans urinary tract[75-85]. Among them, several works describe the presence of a complex bacterial community with the predominant genera *Lactobacillus, Prevotella* and *Gardnerella*, with a considerable variation featured between individuals[79,83].

Bladder cancer is the most prevalent malignancy of the urinary system. In 2015, it is estimated that 75000 new cases will be diagnosed, and more then 15,000 patients will die due from Bladder cancer in the United States[86]. The most important risk factors known for urothelial carcinoma are cigarette smoking and various occupational exposures. The nematode, *Schistosoma haematobium* infection was also associated with the development of squamous cell carcinoma of bladder due to chronic inflammation. Regarding microbiome involvement in urothelial carcinoma, a study comparing the microbiome of urine specimens from healthy individuals and urothelial carcinoma revealed that *Streptococcus* was nearly undetected in normal samples but significantly elevated in 5 out of the 8 cancer samples. *Pseudomonas* or *Anaerococcus* were the most abundant genus in 2 out of the 3 cancer samples where *Streptococcus* abundance was low[87]. While descriptional in nature, this study suggests that urothelial carcinoma may be associated with altered microbiota of the urinary tract. More studies are needed to establish whether microbiome composition plays a role in bladder cancer.

**RENAL** **CANCER**

The role of the healthy microbiome on kidney cancer has not been studied to date. However, a number of studies suggested an association between viral infections and risk of renal cancer, yet these remain controversial and at times contradictory to each other[72,88,89]. One virus that has been implicated in RCC pathology is HPV. One study reported that 7 out of 49 RCC samples to be HPVpositive[90]. A second study, including histology samples of 122 patients, found 30.3% of RCC tumor tissues to be HPVpositive. Of these, 45% were positive for high-risk (HR)-HPVs such as HPV-16 and HPV-18. Moreover, HR-HPV infection correlated with the expression of p16INK4a, a viral immunosuppressant. The authors hypothesized that HR-HPV infection may precede RCC and promote oncogenesis[91]. However, more research is required to test this hypothesis.

In contrast, Newcastle disease virus (NDV) has been suggested in *in vitro* studies to play a therapeutic role in RCC. This virus preferentially infects cancer cells and, upon infection induces apoptosis *via* the p38 MAPK/NF-κB/IκBα pathway. Similar outcomes were obtained in other cancer types[92]. Future studies are needed to translate these *in vitro* findings to the clinical context.

***Respiratory tract***

**Lung:** The human microbiota is the body’s first interface with environmental exposures. In this sense, the lung microbiota may play an important role in the body’s response to airborne carcinogens. The mechanisms of lung carcinogenesis are still not fully understood. The current most important risk factor for lung cancer is smoking. In non-smokers, suggested risk factors include environmental tobacco smoke, exposure to radon gas, cooking oil vapors, indoor coal and wood burning, asbestos, genetic factors, parasitic infections as well as viral and bacterial agents[93] that will be described below.

**VIRAL INVOLVEMENT IN LUNG CANCER**

As in skin carcinoma, HPV has been associated with lung cell malignancies (reviewed in detail in[94]). Studies suggest a link between HPV infection and lung cancer in non-smoking patients; it has been shown that epithelial changes in bronchial carcinoma closely resembled HPV-induced genital lesions[95]. Similarly to the mechanisms by which HPV contributes to skin cancer susceptibility, it is suggested that the molecular mechanism of transformation by HPV is mediated by its oncoproteins E5, E6 and E7. In addition, *in vivo* data show HPV integration, E6/E7 expression and down regulation of p53 in lung cancers, further supporting this classical oncogenic mechanism[96].

**BACTERIAL INVOLVEMENT IN LUNG CANCER**

*C. pneumoniae* is a gram-negative obligatory intracellular bacterium and a common cause of pneumonia[69]. *C. pneumoniae* can also cause other conditions, such as sinusitis, bronchitis, rhinitis and worsening of chronic obstructive pulmonary disease (COPD). However, infection can also be asymptomatic. The involvement of *C. pneumoniae* infection in lung cancer development and risk has been suggested by several studies[97-99]. However, the mechanisms for this association remain unclear[100,101]. Pulmonary infections with gram-negative bacteria have also been suggested to contribute to lung metastasis. Acute lung infection models induced by either infection with *E. coli* or administration of LPS increased cancer cell homing to the lung and enhanced lung metastasis[102]. Moreover, the broncho-alveolar lavage fluid from LPS- or *E. coli*-injected mice induced the migration of transformed cells *in vivo*. The tumor cells migratory activity was blocked by AMD3100, a chemokine receptor-4 inhibitor, as well as by amoxicillin, an antibacterial agent. In addition, tracking of the metastatic tumor cell line in the mouse showed that bacteria injection enhanced early localization of the tumor cells to the lung.

The bacterium *C. pneumoniae* is a gram-negative obligatory intracellular bacterium and a common cause of pneumonia[101]. In addition to pneumonia, *C. pneumoniae* can cause other conditions, such as sinusitis, bronchitis, rhinitis, exacerbation of chronic obstructive pulmonary disease (COPD). However, infection can also be asymptomatic. The association of *C. pneumoniae* infection with lung cancer risk has been suggested by multiple studies[97-99], although the mechanisms for this association remain unclear[100,103].

Pulmonary infections with gram-negative bacteria have also been suggested to contribute to lung metastasis. Acute lung infection models induced by either infection with *E. coli* or administration of LPS increased cancer cell homing to the lung and enhanced lung metastasis[102]. Moreover, the broncho-alveolar lavage (BAL) fluid from LPS- or *E. coli*-injected mice stimulated migration of tumor cells *in vivo*. The tumor cells migratory activity could be blocked by AMD3100, a chemokine receptor-4 (CXCR4) inhibitor, as well as by the antibacterial agent amoxicillin. In addition, *in vivo* tracking of the metastatic tumor cell line showed that bacterial injection enhanced early dissemination of the tumor cells to the lung.

In contrast, antibiotics-treated mice were shown to be more susceptible to tumor development in the lungs after inoculation with B16/F10 melanoma or a lung carcinoma cell-line. In this model, commensal bacteria were found to be essential for the function of γδ-Th17 cells in the lung, and the absence of these cells increased the susceptibility to lung carcinoma and B16/F10 melanoma development[87]. This indicates, that the antitumor defense of the host through γδ-Th17 cells is dependent on an intact microbiome composition. Therewith, lung cancer is an excellent example of the healthy microbiome playing a protective role in tumorigeneis, whereas when dysbiosis develops, pathogenic or pathobiont bacteria may promote, in certain contexts, cancer development.

***Liver***

Primary liver cancer is the fifth most diagnosed form of cancer in males, and the second most frequent cause of cancer death worldwide. Seventy percent to ninety percent of the primary liver cancer cases can be classified as hepatocellular carcinoma (HCC)[104,105]. With mortality to incidence ratio of 0.95, the prognosis for patients with HCC is extremely poor[105]. In developed countries, chronic HBV and HCV infections account for approximately 43% of cases. However, the majority of patients develop HCC secondary to alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD)[104]. It has recently been suggested that the microbiota plays an important role in HCC development. Although the liver, under normal conditions, is considered sterile, its environment is greatly influenced by the nutrients, metabolites and also toxins and pathogens derived from the gut *via* the portal vein. Therefore, the composition in the gut microbiota can greatly influence the functioning of the liver, by its myriad metabolic activities regulating the gut liver axis. Indeed, recent studies have suggested that the composition of the gut microbiota can both influence the development of diseases predisposing to HCC such as chronic HBV and HCV infections, ALD and NAFLD, and the transition from these diseases into HCC[106,107], yet the mechanisms driving these effects remain elusive.

**VIRAL CONTRIBUTION TO HCC**

The majority of HCC cases occur in patients previously suffering of chronic hepatotrophic viral infection, mainly HBV and HCV[108]. A unique feature of HBV infection is that while 95% of adults are able to spontaneously clear the virus, over 90% of neonates and approximately 30% of children aged 1-5 develop persistent infection[109,110]. Possible involvement of the microbiota in this phenomenon was suggested from a study in which mice treated with oral antibiotics for 6 wk prior to HBV infection were no longer able to rapidly clear the virus[111]. Further experiments indicate that the microbiota in young mice may induce HBV tolerance in the liver *via* LPS-TLR4 mediated secretion of IL-10 by kupffer cells (KC), whereas the mature microbiota shifts this balance towards clearance of the virus by stimulating KC-dependent lymphoid organization and tissue priming in the liver[111,112]. Future studies are needed to further validate this interesting association, and to determine possible roles of the gut microbiota in the clearance of other hepatotrophic viruses such as HCV.

Both HBV and HCV infections contribute to the development of HCC by promoting a pro-inflammatory liver micro-environment, affecting cell cycle regulation and inducing ER stress, as has been extensively reviewed elsewhere[113]. However, a study by Fox *et al*[114] indicated that colonization with *H. hepaticus* in the gut was sufficient to promote HCC in HCV-transgenic mice, in the absence of either translocation of *H. hepaticus* to the liver or overt hepatitis. From its niche in the intestinal mucosa, *H.* *hepaticus* activated NF-κB dependent networks associated with innate and T-helper 1 (Th-1)-type adaptive immunity, both in the intestines and in the liver. The resultant transcriptional changes promoted the development of pre-neoplastic and neoplastic liver foci in mice bearing an HCV transgene, while neither factor by itself was sufficient to induce tumor formation[114]. This demonstrates that *H.* *hepaticus* can alter hepatic immune regulation from its intestinal niche, in a manner that synergizes with viral tumorigenic factors. More research is warranted to uncover whether other changes in the intestinal microbiota can induce similar effect.

**BACTERIAL CONTRIBUTION TO HCC**

Chronic alcoholic consumption is considered a major risk factor for chronic liver disease and HCC. Already in 1991 it was noted that patients with alcoholic cirrhosis displayed far higher levels of serum endotoxin than those with non-alcoholic cirrhosis, suggesting that alcoholic cirrhosis is associated with impaired intestinal barrier function[115]. Likewise, treatment of rats with antibiotics targeting Gram-negative bacteria drastically decreased serum endotoxin levels and liver injury in ethanol-fed rats[116]. These suggested that some of the features of chronic alcohol toxicity may be mediated by gut-associated pathogen-induced molecular patterns (PAMPS) released by the gut microbiota. These findings were further confirmed, with the finding that germ-free mice, which are devoid of a microbiota, are protected from ethanol-induced liver disease[117]. Moreover, transplanting microbiota from alcohol-fed mice into naive germ-free mice was sufficient to induce liver injury and inflammation. Furthermore, excessive alcohol intake lead to dysbiosis by an overgrowth of Gram-negative bacteria, that caused increased gut permeability. As leaky gut leads to increased availability of bacterial metabolites to the liver, as well as pro-inflammatory molecules such as bacterial toxins, LPS and even living microbes, this may explain how alcohol-induced dysbiosis could lead to ALD. Indeed, feeding mice a high-fiber diet partially prevented alcohol-induced dysbiosis, decreased gut permeability and mitigated the damage to the liver[117]. This model is supported by preliminary data from patients with alcoholic cirrhosis that show an increase in Gram-negative bacteria as well as an increased bacterial translocation to the liver[118], suggesting that microbiota-targeting interventions may potentially mitigate alcohol-induced liver damage.

Alcohol-induced liver cirrhosis is characterized by cellular injury, inflammation, and fibrosis coupled with compensatory cell growth and proliferation, conditions promoting tumor development[119]. Furthermore, ethanol can induce epigenetic changes in hepatocytes that lead to tumor formation[120]. There is evidence that ethanol-mediated TLR4 signaling is crucial in the dedifferentiation of hepatocytes seen in HBV/HCV- and ALD-associated HCC. Ethanol-induced hepatic translocation of LPS and gram-negative bacteria may further synergize with these direct effects in activating the innate immune response. In agreement, diethylnitrosamine (DEN)-induced liver cirrhosis was accompanied by dysbiosis. When treated with probiotics, a reduction in gut permeability and intestinal inflammation was observed together with a reduced incidence of cirrhosis and HCC in this model[121]. Together, these studies suggest that ALD-associated dysbiosis may contribute to HCC susceptibility.

NAFLD, a component of the “metabolic syndrome”, is rapidly becoming a common cause of chronic liver disease in both developed and developing countries[122]. While most patients with NAFLD feature isolated liver steatosis, in approximately 20% of cases NAFLD evolves into non-alcoholic steatohepatitis (NASH), a progressive liver disease involving a combination of steatosis, hepatocellular damage, inflammation and fibrosis. NASH has the potential to develop into cirrhosis, which is a major risk factor for HCC as described above. In addition, there has been also a rising incidence of NAFLD-associated HCC in the absence of cirrhosis[122,123]. It is unclear to what extent the pathophysiology for NAFLD-associated HCC in the absence of cirrhosis differs from that in a cirrhotic liver. The microbiota has been described to contribute to this *via* two distinct pathways, which may play a role in either situation.

Obesity has been associated with dysbiosis and increased gut permeability, allowing for more LPS to translocate into the liver, where it can trigger TLR signaling resulting in NF-κB-dependent transcription of TNF-α, which drives NAFLD and NASH progression[106,124]. This state is further aggravated as leptin-mediated up-regulation of CD14 leads to hypersensitivity to LPS-signals in obese patients[125]. Furthermore, microbiota-induced TLR9 signaling and dysbiosis-induced repression of inflammasome signaling can further promote the development of NAFLD and NASH[106]. In this context, increased activation of Kupffer cells *via* TLR4 further exacerbates steatohepatitis[126] and promotes the activation of hepatic stellate cells (HSCs). Activated HSCs, in turn, can contribute to liver fibrosis as well as secrete EGFR, which leads to increased proliferation of HSCs and may promote tumor formation[127]. Nonetheless, a study by Dianne *et al*[128] suggested that the gut microbiota may not be required for HCC initiation. Instead, it plays a major role in the progression of the disease, as TLR4 signaling was able to increase the expression of the hepatomitogen epiregulin as well as to promote proliferation and prevent apoptosis. Both sterilization of the gut during late stages of HCC as well as using a TLR4-/- model greatly reduced the progression of HCC, suggesting new avenues of treatment[128].

Whereas mainly gram-negative bacterial LPS drives the pathways above, a second and independent process has been suggested to primarily depend on Gram-positive bacteria. Yoshimoto *et al*[129] showed that an HFD-induced overgrowth of Gram-positive bacteria with the ability to produce the secondary bile acid deoxycholic acid (DCA) *via* 7α-dehydroxylation of primary bile acid lead to a marked rise in serum DCA levels[129]. DCA is known to cause DNA damage through the production of reactive oxygen species (ROS), as well as to promote liver carcinogenesis[130,131]. Furthermore, DCA can induce a state of senescence accompanied by the secretion of specific chemokines, called the senescence-associated secretory phenotype (SASP)[132,133]. Indeed, the authors showed DCA is able to induce SASP in HSCs *in vivo*. This phenotype then promoted HCC development in mice treated with a chemical carcinogen. By blocking DCA production or treating mice with vancomycin, an antibiotic preferentially targeting Gram-positive bacteria, the induction of SASP and the progression of HCC could almost completely be blocked. When antibiotic treatment was supplemented with DCA, the beneficial effect was lost. It should be noted, however, that treating lean mice with a carcinogen and DCA was not sufficient to enhance HCC development. This suggests that additional, obesity-associated tumor-promoting factors may be required[129]. Nonetheless, some preclinical studies have showed that probiotic treatment can substantially alter bile acid levels by increasing fecal secretion and enhancing hepatic bile synthesis[134]. In humans, who unlike rodents cannot revert DCA into cholic acid, DCA can accumulate until it represents > 50% of the total bile pool[135]. Enhanced secretion of bile acids accompanied by hepatic bile synthesis might be a clean way to lower DCA levels, which in turn may substantially decrease the progression of HCC.

Increasing evidence suggests that the microbial composition plays a crucial role mediating liver damage in response to hepatitis infections, excessive alcohol intake or obesity. As HCC rarely occurs without previous liver disease, modulating the microbiota to prevent primary damage would be a potentially effective method of HCC prevention. However, even after liver disease has developed, the microbiota plays an important role in its progression and in creating a tumorigenic environment, through bacterial signaling *via* toxins, LPS and metabolites. Although the bile acid-driven pathophysiology seems specific to NAFLD-associated HCC, the LPS-TLR4 pathway appears common to all cirrhosis-associated HCC entities. While human microbiome-HCC clinical correlations remain preliminary, they represent a potential new avenue for HCC prevention and treatment, which merits further studies.

***Pancreas***

Pancreatic cancer is associated with a poor outcome due to its rapid dissemination through the lymphatic system. This aggressive biology combined with a lack of biomarkers for early detection and resistance to conventional therapy results in a 5-year survival rate of only 5%[136].

Suggestions for possible microbial involvement in pancreatic cancer comes from studies that found an epidemiological association between periodontitis and tooth loss, and the risk for pancreatic cancer[137,138]. However, a study by Stolzenberg *et al*[139] trying to correlate this with a specific bacterium known to play a role in tumor formation, *Helicobactor pylori*, was unable to validate the association. Unlike Stolzenberg, Farell *et al*[140] decided to study the entire composition of the oral microbiome in relation to pancreatic cancer. In this work, researchers identified a total of 56 clusters of bacterial species to be changed significantly between patients with pancreatic cancer and healthy controls. A combination of two bacteria, *N elongata* and *S mitisas*, was suggested as a possible biomarker for the detection of pancreatic cancer. Although these results may allow for a better detection of pancreatic cancer, further research is required to understand whether these changes in the oral microbiota are causative and contribute to the pathogenesis of pancreatic cancer.

Mitsuhashi *et al*[141] took an entirely different approach in studying the role of the local pancreatic microbiota in cancer development. From a large databank of pancreatic cancer tissue specimens, they tested samples for the presence of an oral microbe group, *Fusobacterium*, in the pancreatic tissue. Members of *Fusobacterium* have been implicated in periodontitis as well as pancreatic abscesses and CRC[142,143]. Mithuhashi *et al*[141] detected *Fusobacterium* in 8.8% of the samples. Despite a lack of correlation between these taxa and the molecular characteristics of the tumor tissue, the *Fusobacterium-*positive patients featured a higher rate of cancer-associated mortality than those without detectable microbial inoculation[141].

While these two studies suggest there may be some role for the oral and/or local pancreatic microbiota in the pathology of pancreatic cancer, they remain purely correlative. Further research is required to determine the causative role and mechanisms of activity through which microbial infection influences the occurrence or progression of pancreatic cancer.

**CONCLUSION**

Among the microbes affecting cancer development and progression, viruses are a major pathogenic cause of carcinogenesis in non-gastrotintestinal tumors, through some well-established molecular mechanisms[144]. In addition, specific bacterial pathogens have been described to induce or contribute to carcinogenesis in these entities. Bacterial mechanisms implicated in carcinogenesis include directly DNA-damaging toxin secretion, induction of chronic inflammation and suppression of immune cell activation[4,145,146]. However, the promotion of cancer formation can also result from compositional and functional changes in the microbiome configuration as a whole. When considering the role of the microbiome in cancer, a distinction should be made between local and systemic microbiome-associated effects. Currently, most studies focus on local effects of organ-specific microbiomes, such as those illustrated for the lung microbiome that may contribute to the development of lung cancer. Nonetheless, research into HCC revealed that the gut microbiota might influence carcinogenesis at distal organs, such as the sterile liver. In this particular case, the liver is anatomically linked to the gut *via* the portal vein, thereby efflux of gut microbiome-secreted or modulated metabolites may provide a mechanism linking gut microbes to hepatic carcinogenesis. However, multiple other studies[147,148] recently suggested that the gut microbiome is also able to induce systemic and long-term changes in the immune system, thereby providing possible mechanisms by which one microbiome may contribute to cancer pathogenesis even in anatomically distinct organs.

Another focus of intense research is aimed at deciphering the mechanisms governing microbiota composition, which are currently thought to be determined by a balance between the state of the host and particularly its immune system and the microbial configuration that inhabits it[106,107,149]. When one of these components is disturbed the altered “dysbiotic” microbiota may contribute to the emergence of multifactorial disease, yet the mechanisms regulating these alterations and their consequences remain elusive. Indeed, in this review, we show examples for how alterations in host microbiota interactions may be involved in cancer promotion and progression. For example, Host immune alterations, such as TLR-5 deficiency may lead to tumor progression by its altered microbiota components[128,150]. In other cases, a single microbial component, such as Hepatitis B or C virus, may directly promote carcinogenesis[108]. Finally, we provide examples suggesting that a pathogen or a pathobiont may alter the whole microbiota composition and function, thereby indirectly promoting cancer development. For instance, multiple independent studies showed that the composition of the vaginal microbiota differs between individuals infected or uninfected with HPV[65,112]. Future studies merit elucidation of causality of these associations in promoting carcinogenesis, as well as delineating the mechanisms driving these effects.

Another currently unanswered question relates to the nature of microbe-microbe interactions in driving homeostasis or cancer susceptibility. Until recently, involvement of microorganisms in cancer development was an area of research dominated by studies implicating viral agents. This has recently changed as studies focusing on bacterial composition suggested that the bacterial microbiome may be involved, at steady state, in prevention of tumor development and when altered may participate in carcinogenesis. Studies focusing on the roles of interactions between the viral and bacterial microbiome components (such as phages affecting the composition of the bacterial microbiome) will add yet another complexity to our understanding of host-microbe interactions in cancer and merit further studies.

In summary, the host and the microbiome are increasingly regarded as two integral components of the “holobiome”, and extensively interact through a complex communication network. As such, the host and its microbiome continuously affect each other and cooperate in inducing and maintaining a healthy steady state homeostasis. Alterations of the host-microbiome communications results in breech of normal interactions, and when coupled to host germ-line encoded disease susceptibility risks, may lead to emergence of multi-factorial diseases, such as cancer. A more thorough understanding of the underlying mechanisms that govern this balance of protective and cancer-promoting effects of the host and its microbiome will highlight new therapeutic targets, offering novel avenues of therapy. In years to come extensive research will likely focus on the roles of the tumor and organ-specific microbiome in cancer development and progression, effects of one microbiome (such as the gut microbiome) on tumoregenesis in other locations, the effects of microbiome alterations (dysbiosis) on immune function and hence tumor immunity, and the possible roles of other commensal microbial kingdoms, such as fungi, archaea and parasites, and of environmental triggers in cancer biology.

**ACKNOWLEDGEMENTS**

We thank the members of the Elinav lab for fruitful discussions. We apologize for authors whose works were not included in this review due to space limitations.

**REFERENCES**

1 **Kau AL**, Ahern PP, Griffin NW, Goodman AL, Gordon JI. Human nutrition, the gut microbiome and the immune system. *Nature* 2011; **474**: 327-336 [PMID: 21677749 DOI: 10.1038/nature10213]

2 **Balkwill F**, Mantovani A. Inflammation and cancer: back to Virchow? *Lancet* 2001; **357**: 539-545 [PMID: 11229684 DOI: 10.1016/S0140-6736(00)04046-0]

3 **Trinchieri G**. Cancer and inflammation: an old intuition with rapidly evolving new concepts. *Annu Rev Immunol* 2012; **30**: 677-706 [PMID: 22224761 DOI: 10.1146/annurev-immunol-020711-075008]

4 **Fox JG**, Wang TC. Inflammation, atrophy, and gastric cancer. *J Clin Invest* 2007; **117**: 60-69 [PMID: 17200707 DOI: 10.1172/JCI30111]

5 **Couturier-Maillard A**, Secher T, Rehman A, Normand S, De Arcangelis A, Haesler R, Huot L, Grandjean T, Bressenot A, Delanoye-Crespin A, Gaillot O, Schreiber S, Lemoine Y, Ryffel B, Hot D, Nùñez G, Chen G, Rosenstiel P, Chamaillard M. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. *J Clin Invest* 2013; **123**: 700-711 [PMID: 23281400 DOI: 10.1172/JCI62236]

6 **Hu B**, Elinav E, Huber S, Strowig T, Hao L, Hafemann A, Jin C, Wunderlich C, Wunderlich T, Eisenbarth SC, Flavell RA. Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer. *Proc Natl Acad Sci USA* 2013; **110**: 9862-9867 [PMID: 23696660 DOI: 10.1073/pnas.1307575110]

7 **Keku TO**, Dulal S, Deveaux A, Jovov B, Han X. The gastrointestinal microbiota and colorectal cancer. *Am J Physiol Gastrointest Liver Physiol* 2015; **308**: G351-G363 [PMID: 25540232 DOI: 10.1152/ajpgi.00360.2012]

8 **Bromberg JS**, Fricke WF, Brinkman CC, Simon T, Mongodin EF. Microbiota—implications for immunity and transplantation. *Nat Rev Nephrol* 2015; **11**: 342-353 [PMID: 25963591 DOI: 10.1038/nrneph.2015.70]

9 **Garrett WS**. Cancer and the microbiota. *Science* 2015; **348**: 80-86 [PMID: 25838377 DOI: 10.1126/science.aaa4972]

10 **Schwabe RF**, Jobin C. The microbiome and cancer. *Nat Rev Cancer* 2013; **13**: 800-812 [PMID: 24132111 DOI: 10.1038/nrc3610]

11 **Wlodarska M**, Kostic AD, Xavier RJ. An integrative view of microbiome-host interactions in inflammatory bowel diseases. *Cell Host Microbe* 2015; **17**: 577-591 [PMID: 25974300 DOI: 10.1016/j.chom.2015.04.008]

12 **Findley K**, Oh J, Yang J, Conlan S, Deming C, Meyer JA, Schoenfeld D, Nomicos E, Park M, Kong HH, Segre JA. Topographic diversity of fungal and bacterial communities in human skin. *Nature* 2013; **498**: 367-370 [PMID: 23698366 DOI: 10.1038/nature12171]

13 **Oh J**, Byrd AL, Deming C, Conlan S, Kong HH, Segre JA. Biogeography and individuality shape function in the human skin metagenome. *Nature* 2014; **514**: 59-64 [PMID: 25279917 DOI: 10.1038/nature13786]

14 **Oh J**, Conlan S, Polley EC, Segre JA, Kong HH. Shifts in human skin and nares microbiota of healthy children and adults. *Genome Med* 2012; **4**: 77 [PMID: 23050952 DOI: 10.1186/gm378]

15 **Foulongne V**, Sauvage V, Hebert C, Dereure O, Cheval J, Gouilh MA, Pariente K, Segondy M, Burguière A, Manuguerra JC, Caro V, Eloit M. Human skin microbiota: high diversity of DNA viruses identified on the human skin by high throughput sequencing. *PLoS One* 2012; **7**: e38499 [PMID: 22723863 DOI: 10.1371/journal.pone.0038499]

16 **Bravo IG**, Félez-Sánchez M. Papillomaviruses: Viral evolution, cancer and evolutionary medicine. *Evol Med Public Health* 2015; **2015**: 32-51 [PMID: 25634317 DOI: 10.1093/emph/eov003]

17 **Antonsson A**, Forslund O, Ekberg H, Sterner G, Hansson BG. The ubiquity and impressive genomic diversity of human skin papillomaviruses suggest a commensalic nature of these viruses. *J Virol* 2000; **74**: 11636-11641 [PMID: 11090162]

18 **Feng H**, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. *Science* 2008; **319**: 1096-1100 [PMID: 18202256 DOI: 10.1126/science.1152586]

19 **zur Hausen H**. Novel human polyomaviruses--re-emergence of a well known virus family as possible human carcinogens. *Int J Cancer* 2008; **123**: 247-250 [PMID: 18449881 DOI: 10.1002/ijc.23620]

20 **Shuda M**, Arora R, Kwun HJ, Feng H, Sarid R, Fernández-Figueras MT, Tolstov Y, Gjoerup O, Mansukhani MM, Swerdlow SH, Chaudhary PM, Kirkwood JM, Nalesnik MA, Kant JA, Weiss LM, Moore PS, Chang Y. Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors. *Int J Cancer* 2009; **125**: 1243-1249 [PMID: 19499546 DOI: 10.1002/ijc.24510]

21 **Costello EK**, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight R. Bacterial community variation in human body habitats across space and time. *Science* 2009; **326**: 1694-1697 [PMID: 19892944 DOI: 10.1126/science.1177486]

22 **Faust K**, Sathirapongsasuti JF, Izard J, Segata N, Gevers D, Raes J, Huttenhower C. Microbial co-occurrence relationships in the human microbiome. *PLoS Comput Biol* 2012; **8**: e1002606 [PMID: 22807668 DOI: 10.1371/journal.pcbi.1002606]

23 **Grice EA**, Kong HH, Conlan S, Deming CB, Davis J, Young AC, Bouffard GG, Blakesley RW, Murray PR, Green ED, Turner ML, Segre JA. Topographical and temporal diversity of the human skin microbiome. *Science* 2009; **324**: 1190-1192 [PMID: 19478181 DOI: 10.1126/science.1171700]

24 **Grice EA**, Kong HH, Renaud G, Young AC, Bouffard GG, Blakesley RW, Wolfsberg TG, Turner ML, Segre JA. A diversity profile of the human skin microbiota. *Genome Res* 2008; **18**: 1043-1050 [PMID: 18502944 DOI: 10.1101/gr.075549.107]

25 **Gao Z**, Tseng CH, Pei Z, Blaser MJ. Molecular analysis of human forearm superficial skin bacterial biota. *Proc Natl Acad Sci USA* 2007; **104**: 2927-2932 [PMID: 17293459 DOI: 10.1073/pnas.0607077104]

26 **Hannigan GD**, Grice EA. Microbial ecology of the skin in the era of metagenomics and molecular microbiology. *Cold Spring Harb Perspect Med* 2013; **3**: a015362 [PMID: 24296350 DOI: 10.1101/cshperspect.a015362]

27 **Hoste E**, Arwert EN, Lal R, South AP, Salas-Alanis JC, Murrell DF, Donati G, Watt FM. Innate sensing of microbial products promotes wound-induced skin cancer. *Nat Commun* 2015; **6**: 5932 [PMID: 25575023 DOI: 10.1038/ncomms6932]

28 **Jemal A**, Siegel R, Xu J, Ward E. Cancer statistics, 2010. *CA Cancer J Clin* 2010; **60**: 277-300 [PMID: 20610543 DOI: 10.3322/caac.20073]

29 **Madigan MP**, Ziegler RG, Benichou J, Byrne C, Hoover RN. Proportion of breast cancer cases in the United States explained by well-established risk factors. *J Natl Cancer Inst* 1995; **87**: 1681-1685 [PMID: 7473816]

30 **Lakritz JR**, Poutahidis T, Mirabal S, Varian BJ, Levkovich T, Ibrahim YM, Ward JM, Teng EC, Fisher B, Parry N, Lesage S, Alberg N, Gourishetti S, Fox JG, Ge Z, Erdman SE. Gut bacteria require neutrophils to promote mammary tumorigenesis. *Oncotarget* 2015; **6**: 9387-9396 [PMID: 25831236

31 **Xuan C**, Shamonki JM, Chung A, Dinome ML, Chung M, Sieling PA, Lee DJ. Microbial dysbiosis is associated with human breast cancer. *PLoS One* 2014; **9**: e83744 [PMID: 24421902 DOI: 10.1371/journal.pone.0083744]

32 **Akil N**, Yasmeen A, Kassab A, Ghabreau L, Darnel AD, Al Moustafa AE. High-risk human papillomavirus infections in breast cancer in Syrian women and their association with Id-1 expression: a tissue microarray study. *Br J Cancer* 2008; **99**: 404-407 [PMID: 18648363 DOI: 10.1038/sj.bjc.6604503]

33 **Heng B**, Glenn WK, Ye Y, Tran B, Delprado W, Lutze-Mann L, Whitaker NJ, Lawson JS. Human papilloma virus is associated with breast cancer. *Br J Cancer* 2009; **101**: 1345-1350 [PMID: 19724278 DOI: 10.1038/sj.bjc.6605282]

34 **Kroupis C**, Markou A, Vourlidis N, Dionyssiou-Asteriou A, Lianidou ES. Presence of high-risk human papillomavirus sequences in breast cancer tissues and association with histopathological characteristics. *Clin Biochem* 2006; **39**: 727-731 [PMID: 16780823 DOI: 10.1016/j.clinbiochem.2006.03.005]

35 **Gopalkrishna V**, Singh UR, Sodhani P, Sharma JK, Hedau ST, Mandal AK, Das BC. Absence of human papillomavirus DNA in breast cancer as revealed by polymerase chain reaction. *Breast Cancer Res Treat* 1996; **39**: 197-202 [PMID: 8872328]

36 **Lindel K**, Forster A, Altermatt HJ, Greiner R, Gruber G. Breast cancer and human papillomavirus (HPV) infection: no evidence of a viral etiology in a group of Swiss women. *Breast* 2007; **16**: 172-177 [PMID: 17088061 DOI: 10.1016/j.breast.2006.09.001]

37 **Bonnet M**, Guinebretiere JM, Kremmer E, Grunewald V, Benhamou E, Contesso G, Joab I. Detection of Epstein-Barr virus in invasive breast cancers. *J Natl Cancer Inst* 1999; **91**: 1376-1381 [PMID: 10451442]

38 **Fina F**, Romain S, Ouafik L, Palmari J, Ben Ayed F, Benharkat S, Bonnier P, Spyratos F, Foekens JA, Rose C, Buisson M, Gérard H, Reymond MO, Seigneurin JM, Martin PM. Frequency and genome load of Epstein-Barr virus in 509 breast cancers from different geographical areas. *Br J Cancer* 2001; **84**: 783-790 [PMID: 11259092 DOI: 10.1054/bjoc.2000.1672]

39 **Luqmani Y**, Shousha S. Presence of epstein-barr-virus in breast-carcinoma. *Int J Oncol* 1995; **6**: 899-903 [PMID: 21556618]

40 **McCall SA**, Lichy JH, Bijwaard KE, Aguilera NS, Chu WS, Taubenberger JK. Epstein-Barr virus detection in ductal carcinoma of the breast. *J Natl Cancer Inst* 2001; **93**: 148-150 [PMID: 11208885]

41 **Glaser SL**, Ambinder RF, DiGiuseppe JA, Horn-Ross PL, Hsu JL. Absence of Epstein-Barr virus EBER-1 transcripts in an epidemiologically diverse group of breast cancers. *Int J Cancer* 1998; **75**: 555-558 [PMID: 9466655]

42 **Lespagnard L**, Cochaux P, Larsimont D, Degeyter M, Velu T, Heimann R. Absence of Epstein-Barr virus in medullary carcinoma of the breast as demonstrated by immunophenotyping, in situ hybridization and polymerase chain reaction. *Am J Clin Pathol* 1995; **103**: 449-452 [PMID: 7726142]

43 **Reddy BS**, Watanabe K. Effect of intestinal microflora on 2,2'-dimethyl-4-aminobiphenyl-induced carcinogenesis in F344 rats. *J Natl Cancer Inst* 1978; **61**: 1269-1271 [PMID: 280712]

44 **Rutkowski MR**, Stephen TL, Svoronos N, Allegrezza MJ, Tesone AJ, Perales-Puchalt A, Brencicova E, Escovar-Fadul X, Nguyen JM, Cadungog MG, Zhang R, Salatino M, Tchou J, Rabinovich GA, Conejo-Garcia JR. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. *Cancer Cell* 2015; **27**: 27-40 [PMID: 25533336 DOI: 10.1016/j.ccell.2014.11.009]

45 **Whiteside SA**, Razvi H, Dave S, Reid G, Burton JP. The microbiome of the urinary tract--a role beyond infection. *Nat Rev Urol* 2015; **12**: 81-90 [PMID: 25600098 DOI: 10.1038/nrurol.2014.361]

46 **Doorbar J**. The papillomavirus life cycle. *J Clin Virol* 2005; **32** Suppl 1: S7-15 [PMID: 15753007 DOI: 10.1016/j.jcv.2004.12.006]

47 **Moscicki AB**. Impact of HPV infection in adolescent populations. *J Adolesc Health* 2005; **37**: S3-S9 [PMID: 16310138 DOI: 10.1016/j.jadohealth.2005.09.011]

48 **Viscidi RP**, Schiffman M, Hildesheim A, Herrero R, Castle PE, Bratti MC, Rodriguez AC, Sherman ME, Wang S, Clayman B, Burk RD. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. *Cancer Epidemiol Biomarkers Prev* 2004; **13**: 324-327 [PMID: 14973086]

49 **Viscidi RP**, Snyder B, Cu-Uvin S, Hogan JW, Clayman B, Klein RS, Sobel J, Shah KV. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. *Cancer Epidemiol Biomarkers Prev* 2005; **14**: 283-288 [PMID: 15668510]

50 **Romanowski B**, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, Somani R, Barbier S, Blatter MM, Chambers C, Ferris D, Gall SA, Guerra FA, Harper DM, Hedrick JA, Henry DC, Korn AP, Kroll R, Moscicki AB, Rosenfeld WD, Sullivan BJ, Thoming CS, Tyring SK, Wheeler CM, Dubin G, Schuind A, Zahaf T, Greenacre M, Sgriobhadair A. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. *Lancet* 2009; **374**: 1975-1985 [PMID: 19962185 DOI: 10.1016/S0140-6736(09)61567-1]

51 **Olsson SE**, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ, Barr E. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. *Vaccine* 2007; **25**: 4931-4939 [PMID: 17499406 DOI: 10.1016/j.vaccine.2007.03.049]

52 **Harper DM**, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. *Lancet* 2006; **367**: 1247-1255 [PMID: 16631880 DOI: 10.1016/S0140-6736(06)68439-0]

53 **Paavonen J**, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. *Lancet* 2009; **374**: 301-314 [PMID: 19586656 DOI: 10.1016/S0140-6736(09)61248-4]

54 **Villa LL**, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh Gv, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. *Br J Cancer* 2006; **95**: 1459-1466 [PMID: 17117182 DOI: 10.1038/sj.bjc.6603469]

55 **Martin DH**. The microbiota of the vagina and its influence on women's health and disease. *Am J Med Sci* 2012; **343**: 2-9 [PMID: 22143133 DOI: 10.1097/MAJ.0b013e31823ea228]

56 **Boskey ER**, Cone RA, Whaley KJ, Moench TR. Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source. *Hum Reprod* 2001; **16**: 1809-1813 [PMID: 11527880]

57 **Aroutcheva A**, Gariti D, Simon M, Shott S, Faro J, Simoes JA, Gurguis A, Faro S. Defense factors of vaginal lactobacilli. *Am J Obstet Gynecol* 2001; **185**: 375-379 [PMID: 11518895 DOI: 10.1067/mob.2001.115867]

58 **Ocaña VS**, Pesce De Ruiz Holgado AA, Nader-Macías ME. Characterization of a bacteriocin-like substance produced by a vaginal Lactobacillus salivarius strain. *Appl Environ Microbiol* 1999; **65**: 5631-5635 [PMID: 10584033]

59 **Reid G**, Heinemann C, Velraeds M, van der Mei HC, Busscher HJ. Biosurfactants produced by Lactobacillus. *Methods Enzymol* 1999; **310**: 426-433 [PMID: 10547809]

60 **Boris S**, Barbés C. Role played by lactobacilli in controlling the population of vaginal pathogens. *Microbes Infect* 2000; **2**: 543-546 [PMID: 10865199]

61 **McMillan A**, Dell M, Zellar MP, Cribby S, Martz S, Hong E, Fu J, Abbas A, Dang T, Miller W, Reid G. Disruption of urogenital biofilms by lactobacilli. *Colloids Surf B Biointerfaces* 2011; **86**: 58-64 [PMID: 21497071 DOI: 10.1016/j.colsurfb.2011.03.016]

62 **Brotman RM**, Ghanem KG, Klebanoff MA, Taha TE, Scharfstein DO, Zenilman JM. The effect of vaginal douching cessation on bacterial vaginosis: a pilot study. *Am J Obstet Gynecol* 2008; **198**: 628.e1-628.e7 [PMID: 18295180 DOI: 10.1016/j.ajog.2007.11.043]

63 **Clarke MA**, Rodriguez AC, Gage JC, Herrero R, Hildesheim A, Wacholder S, Burk R, Schiffman M. A large, population-based study of age-related associations between vaginal pH and human papillomavirus infection. *BMC Infect Dis* 2012; **12**: 33 [PMID: 22316377 DOI: 10.1186/1471-2334-12-33]

64 **Clarke MA**, Stefanidis A, Spencer SJ. Postnatal overfeeding leads to obesity and exacerbated febrile responses to lipopolysaccharide throughout life. *J Neuroendocrinol* 2012; **24**: 511-524 [PMID: 22175701 DOI: 10.1111/j.1365-2826.2011.02269.x]

65 **Gao W**, Weng J, Gao Y, Chen X. Comparison of the vaginal microbiota diversity of women with and without human papillomavirus infection: a cross-sectional study. *BMC Infect Dis* 2013; **13**: 271 [PMID: 23758857 DOI: 10.1186/1471-2334-13-271]

66 **Gillet E**, Meys JF, Verstraelen H, Bosire C, De Sutter P, Temmerman M, Broeck DV. Bacterial vaginosis is associated with uterine cervical human papillomavirus infection: a meta-analysis. *BMC Infect Dis* 2011; **11**: 10 [PMID: 21223574 DOI: 10.1186/1471-2334-11-10]

67 **Guo YL**, You K, Qiao J, Zhao YM, Geng L. Bacterial vaginosis is conducive to the persistence of HPV infection. *Int J STD AIDS* 2012; **23**: 581-584 [PMID: 22930296 DOI: 10.1258/ijsa.2012.011342]

68 **King CC**, Jamieson DJ, Wiener J, Cu-Uvin S, Klein RS, Rompalo AM, Shah KV, Sobel JD. Bacterial vaginosis and the natural history of human papillomavirus. *Infect Dis Obstet Gynecol* 2011; **2011**: 319460 [PMID: 21869857 DOI: 10.1155/2011/319460]

69 **Liu SH**, Cummings DA, Zenilman JM, Gravitt PE, Brotman RM. Characterizing the temporal dynamics of human papillomavirus DNA detectability using short-interval sampling. *Cancer Epidemiol Biomarkers Prev* 2014; **23**: 200-208 [PMID: 24130223 DOI: 10.1158/1055-9965.EPI-13-0666]

70 **Fredricks DN**, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. *N Engl J Med* 2005; **353**: 1899-1911 [PMID: 16267321 DOI: 10.1056/NEJMoa043802]

71 **Gajer P**, Brotman RM, Bai G, Sakamoto J, Schütte UM, Zhong X, Koenig SS, Fu L, Ma ZS, Zhou X, Abdo Z, Forney LJ, Ravel J. Temporal dynamics of the human vaginal microbiota. *Sci Transl Med* 2012; **4**: 132ra52 [PMID: 22553250 DOI: 10.1126/scitranslmed.3003605]

72 **Alibek K**, Karatayeva N, Bekniyazov I. The role of infectious agents in urogenital cancers. *Infect Agent Cancer* 2012; **7**: 35 [PMID: 23198689 DOI: 10.1186/1750-9378-7-35]

73 **Idahl A**, Lundin E, Jurstrand M, Kumlin U, Elgh F, Ohlson N, Ottander U. Chlamydia trachomatis and Mycoplasma genitalium plasma antibodies in relation to epithelial ovarian tumors. *Infect Dis Obstet Gynecol* 2011; **2011**: 824627 [PMID: 21811380 DOI: 10.1155/2011/824627]

74 **Ronald A**. The etiology of urinary tract infection: traditional and emerging pathogens. *Am J Med* 2002; **113** Suppl 1A: 14S-19S [PMID: 12113867]

75 **Dong Q**, Nelson DE, Toh E, Diao L, Gao X, Fortenberry JD, Van der Pol B. The microbial communities in male first catch urine are highly similar to those in paired urethral swab specimens. *PLoS One* 2011; **6**: e19709 [PMID: 21603636 DOI: 10.1371/journal.pone.0019709]

76 **Fouts DE**, Pieper R, Szpakowski S, Pohl H, Knoblach S, Suh MJ, Huang ST, Ljungberg I, Sprague BM, Lucas SK, Torralba M, Nelson KE, Groah SL. Integrated next-generation sequencing of 16S rDNA and metaproteomics differentiate the healthy urine microbiome from asymptomatic bacteriuria in neuropathic bladder associated with spinal cord injury. *J Transl Med* 2012; **10**: 174 [PMID: 22929533 DOI: 10.1186/1479-5876-10-174]

77 **Fricke WF**, Maddox C, Song Y, Bromberg JS. Human microbiota characterization in the course of renal transplantation. *Am J Transplant* 2014; **14**: 416-427 [PMID: 24373208 DOI: 10.1111/ajt.12588]

78 **Hilt EE**, McKinley K, Pearce MM, Rosenfeld AB, Zilliox MJ, Mueller ER, Brubaker L, Gai X, Wolfe AJ, Schreckenberger PC. Urine is not sterile: use of enhanced urine culture techniques to detect resident bacterial flora in the adult female bladder. *J Clin Microbiol* 2014; **52**: 871-876 [PMID: 24371246 DOI: 10.1128/JCM.02876-13]

79 **Lewis DA**, Brown R, Williams J, White P, Jacobson SK, Marchesi JR, Drake MJ. The human urinary microbiome; bacterial DNA in voided urine of asymptomatic adults. *Front Cell Infect Microbiol* 2013; **3**: 41 [PMID: 23967406 DOI: 10.3389/fcimb.2013.00041]

80 **Nelson DE**, Van Der Pol B, Dong Q, Revanna KV, Fan B, Easwaran S, Sodergren E, Weinstock GM, Diao L, Fortenberry JD. Characteristic male urine microbiomes associate with asymptomatic sexually transmitted infection. *PLoS One* 2010; **5**: e14116 [PMID: 21124791 DOI: 10.1371/journal.pone.0014116]

81 **Pearce MM**, Hilt EE, Rosenfeld AB, Zilliox MJ, Thomas-White K, Fok C, Kliethermes S, Schreckenberger PC, Brubaker L, Gai X, Wolfe AJ. The female urinary microbiome: a comparison of women with and without urgency urinary incontinence. *MBio* 2014; **5**: e01283-e01214 [PMID: 25006228 DOI: 10.1128/mBio.01283-14]

82 **Siddiqui H**, Lagesen K, Nederbragt AJ, Jeansson SL, Jakobsen KS. Alterations of microbiota in urine from women with interstitial cystitis. *BMC Microbiol* 2012; **12**: 205 [PMID: 22974186 DOI: 10.1186/1471-2180-12-205]

83 **Siddiqui H**, Nederbragt AJ, Lagesen K, Jeansson SL, Jakobsen KS. Assessing diversity of the female urine microbiota by high throughput sequencing of 16S rDNA amplicons. *BMC Microbiol* 2011; **11**: 244 [PMID: 22047020 DOI: 10.1186/1471-2180-11-244]

84 **Willner D**, Low S, Steen JA, George N, Nimmo GR, Schembri MA, Hugenholtz P. Single clinical isolates from acute uncomplicated urinary tract infections are representative of dominant in situ populations. *MBio* 2014; **5**: e01064-e01013 [PMID: 24570371 DOI: 10.1128/mBio.01064-13]

85 **Wolfe AJ**, Toh E, Shibata N, Rong R, Kenton K, Fitzgerald M, Mueller ER, Schreckenberger P, Dong Q, Nelson DE, Brubaker L. Evidence of uncultivated bacteria in the adult female bladder. *J Clin Microbiol* 2012; **50**: 1376-1383 [PMID: 22278835 DOI: 10.1128/JCM.05852-11]

86 **Siegel R**, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. *CA Cancer J Clin* 2014; **64**: 9-29 [PMID: 24399786 DOI: 10.3322/caac.21208]

87 **Cheng M**, Qian L, Shen G, Bian G, Xu T, Xu W, Shen G, Hu S. Microbiota modulate tumoral immune surveillance in lung through a γδT17 immune cell-dependent mechanism. *Cancer Res* 2014; **74**: 4030-4041 [PMID: 24947042 DOI: 10.1158/0008-5472.CAN-13-2462]

88 **Gordon SC**, Moonka D, Brown KA, Rogers C, Huang MA, Bhatt N, Lamerato L. Risk for renal cell carcinoma in chronic hepatitis C infection. *Cancer Epidemiol Biomarkers Prev* 2010; **19**: 1066-1073 [PMID: 20332260 DOI: 10.1158/1055-9965.EPI-09-1275]

89 **Budakoğlu B**, Aksoy S, Arslan Ç, Üyetürk Ü, Babacan NA, Özcan MF, Yıldız R, Öven BB, Özdemir NY, Dizdar Ö, Büyükberber S, Akıncı MB, Türker I, Öksüzoğlu B, Altundag K, Zengin N. Frequency of HCV infection in renal cell carcinoma patients. *Med Oncol* 2012; **29**: 1892-1895 [PMID: 21461964 DOI: 10.1007/s12032-011-9928-6]

90 **Salehipoor M**, Khezri A, Behzad-Behbahani A, Geramizadeh B, Rahsaz M, Aghdaei M, Afrasiabi MA. Role of viruses in renal cell carcinoma. *Saudi J Kidney Dis Transpl* 2012; **23**: 53-57 [PMID: 22237219]

91 **Farhadi A**, Behzad-Behbahani A, Geramizadeh B, Sekawi Z, Rahsaz M, Sharifzadeh S. High-risk human papillomavirus infection in different histological subtypes of renal cell carcinoma. *J Med Virol* 2014; **86**: 1134-1144 [PMID: 24700118 DOI: 10.1002/jmv.23945]

92 **Ch'ng WC**, Abd-Aziz N, Ong MH, Stanbridge EJ, Shafee N. Human renal carcinoma cells respond to Newcastle disease virus infection through activation of the p38 MAPK/NF-κB/IκBα pathway. *Cell Oncol* (Dordr) 2015; **38**: 279-288 [PMID: 25930675 DOI: 10.1007/s13402-015-0229-5]

93 **Chaturvedi AK**, Gaydos CA, Agreda P, Holden JP, Chatterjee N, Goedert JJ, Caporaso NE, Engels EA. Chlamydia pneumoniae infection and risk for lung cancer. *Cancer Epidemiol Biomarkers Prev* 2010; **19**: 1498-1505 [PMID: 20501758 DOI: 10.1158/1055-9965.EPI-09-1261]

94 **De Paoli P**, Carbone A. Carcinogenic viruses and solid cancers without sufficient evidence of causal association. *Int J Cancer* 2013; **133**: 1517-1529 [PMID: 23280523 DOI: 10.1002/ijc.27995]

95 **Syrjänen KJ**. Condylomatous changes in neoplastic bronchial epithelium. Report of a case. *Respiration* 1979; **38**: 299-304 [PMID: 538337]

96 **Cheng YW**, Wu MF, Wang J, Yeh KT, Goan YG, Chiou HL, Chen CY, Lee H. Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation. *Cancer Res* 2007; **67**: 10686-10693 [PMID: 18006810 DOI: 10.1158/0008-5472.CAN-07-1461]

97 **Grayston JT**. Chlamydia pneumoniae, strain TWAR. *Chest* 1989; **95**: 664-669 [PMID: 2646079]

98 **Laurila AL**, Anttila T, Läärä E, Bloigu A, Virtamo J, Albanes D, Leinonen M, Saikku P. Serological evidence of an association between Chlamydia pneumoniae infection and lung cancer. *Int J Cancer* 1997; **74**: 31-34 [PMID: 9036866]

99 **Zhan P**, Suo LJ, Qian Q, Shen XK, Qiu LX, Yu LK, Song Y. Chlamydia pneumoniae infection and lung cancer risk: a meta-analysis. *Eur J Cancer* 2011; **47**: 742-747 [PMID: 21194924 DOI: 10.1016/j.ejca.2010.11.003]

100 **Kocazeybek B**. Chronic Chlamydophila pneumoniae infection in lung cancer, a risk factor: a case-control study. *J Med Microbiol* 2003; **52**: 721-726 [PMID: 12867569]

101 **Yen MY**, Hu BS, Chen YS, Lee SS, Lin YS, Wann SR, Tsai HC, Lin HH, Huang CK, Liu YC. A prospective etiologic study of community-acquired pneumonia in Taiwan. *J Formos Med Assoc* 2005; **104**: 724-730 [PMID: 16385374]

102 **Yan L**, Cai Q, Xu Y. The ubiquitin-CXCR4 axis plays an important role in acute lung infection-enhanced lung tumor metastasis. *Clin Cancer Res* 2013; **19**: 4706-4716 [PMID: 23690484 DOI: 10.1158/1078-0432.CCR-13-0011]

103 **Koyi H**, Brandén E, Gnarpe J, Gnarpe H, Steen B. An association between chronic infection with Chlamydia pneumoniae and lung cancer. A prospective 2-year study. *APMIS* 2001; **109**: 572-580 [PMID: 11878709]

104 **Perz JF**, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *J Hepatol* 2006; **45**: 529-538 [PMID: 16879891 DOI: 10.1016/j.jhep.2006.05.013]

105 **Lafaro KJ**, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. *Surg Oncol Clin N Am* 2015; **24**: 1-17 [PMID: 25444466 DOI: 10.1016/j.soc.2014.09.001]

106 **Henao-Mejia J**, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, Flavell RA. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. *Nature* 2012; **482**: 179-185 [PMID: 22297845 DOI: 10.1038/nature10809]

107 **Henao-Mejia J**, Elinav E, Thaiss CA, Flavell RA. The intestinal microbiota in chronic liver disease. *Adv Immunol* 2013; **117**: 73-97 [PMID: 23611286 DOI: 10.1016/B978-0-12-410524-9.00003-7]

108 **de Martel C**, Maucort-Boulch D, Plummer M, Franceschi S. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. *Hepatology* 2015; **62**: 1190-1200 [PMID: 26146815 DOI: 10.1002/hep.27969]

109 **Liang TJ**. Hepatitis B: the virus and disease. *Hepatology* 2009; **49**: S13-S21 [PMID: 19399811 DOI: 10.1002/hep.22881]

110 **Ganem D**, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. *N Engl J Med* 2004; **350**: 1118-1129 [PMID: 15014185 DOI: 10.1056/NEJMra031087]

111 **Chou HH**, Chien WH, Wu LL, Cheng CH, Chung CH, Horng JH, Ni YH, Tseng HT, Wu D, Lu X, Wang HY, Chen PJ, Chen DS. Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota. *Proc Natl Acad Sci USA* 2015; **112**: 2175-2180 [PMID: 25646429 DOI: 10.1073/pnas.1424775112]

112 **Publicover J**, Gaggar A, Nishimura S, Van Horn CM, Goodsell A, Muench MO, Reinhardt RL, van Rooijen N, Wakil AE, Peters M, Cyster JG, Erle DJ, Rosenthal P, Cooper S, Baron JL. Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B. *J Clin Invest* 2013; **123**: 3728-3739 [PMID: 23925290 DOI: 10.1172/JCI68182]

113 **Farazi PA**, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. *Nat Rev Cancer* 2006; **6**: 674-687 [PMID: 16929323 DOI: 10.1038/nrc1934]

114 **Fox JG**, Feng Y, Theve EJ, Raczynski AR, Fiala JL, Doernte AL, Williams M, McFaline JL, Essigmann JM, Schauer DB, Tannenbaum SR, Dedon PC, Weinman SA, Lemon SM, Fry RC, Rogers AB. Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. *Gut* 2010; **59**: 88-97 [PMID: 19850960 DOI: 10.1136/gut.2009.183749]

115 **Fukui H**, Brauner B, Bode JC, Bode C. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. *J Hepatol* 1991; **12**: 162-169 [PMID: 2050995]

116 **Adachi Y**, Moore LE, Bradford BU, Gao W, Thurman RG. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. *Gastroenterology* 1995; **108**: 218-224 [PMID: 7806045 DOI: 10.1016/0016-5085(95)90027-6]

117 **M C C C**, N L L, C M F, J L G, D A, C G, G C, S H P, C M, F S M, J R N, M M T, A L B G, A T V. Comparing the effects of acute alcohol consumption in germ-free and conventional mice: the role of the gut microbiota. *BMC Microbiol* 2014; **14**: 240 [PMID: 25223989 DOI: 10.1186/s12866-014-0240-4]

118 **Tuomisto S**, Pessi T, Collin P, Vuento R, Aittoniemi J, Karhunen PJ. Changes in gut bacterial populations and their translocation into liver and ascites in alcoholic liver cirrhotics. *BMC Gastroenterol* 2014; **14**: 40 [PMID: 24564202 DOI: 10.1186/1471-230x-14-40]

119 **Karagozian R**, Derdák Z, Baffy G. Obesity-associated mechanisms of hepatocarcinogenesis. *Metabolism* 2014; **63**: 607-617 [PMID: 24629562 DOI: 10.1016/j.metabol.2014.01.011]

120 **French SW**. Epigenetic events in liver cancer resulting from alcoholic liver disease. *Alcohol Res* 2013; **35**: 57-67 [PMID: 24313165]

121 **Zhang HL**, Yu LX, Yang W, Tang L, Lin Y, Wu H, Zhai B, Tan YX, Shan L, Liu Q, Chen HY, Dai RY, Qiu BJ, He YQ, Wang C, Zheng LY, Li YQ, Wu FQ, Li Z, Yan HX, Wang HY. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. *J Hepatol* 2012; **57**: 803-812 [PMID: 22727732 DOI: 10.1016/j.jhep.2012.06.011]

122 **Baffy G**, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. *J Hepatol* 2012; **56**: 1384-1391 [PMID: 22326465 DOI: 10.1016/j.jhep.2011.10.027]

123 **Torres DM**, Harrison SA. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. *Semin Liver Dis* 2012; **32**: 30-38 [PMID: 22418886 DOI: 10.1055/s-0032-1306424]

124 **Brun P**, Castagliuolo I, Di Leo V, Buda A, Pinzani M, Palù G, Martines D. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. *Am J Physiol Gastrointest Liver Physiol* 2007; **292**: G518-G525 [PMID: 17023554]

125 **Cani PD**, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. *Diabetes* 2008; **57**: 1470-1481 [PMID: 18305141 DOI: 10.2337/db07-1403]

126 **Rivera CA**, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. *J Hepatol* 2007; **47**: 571-579 [PMID: 17644211 DOI: 10.1016/j.jhep.2007.04.019]

127 **Jiang CM**, Pu CW, Hou YH, Chen Z, Alanazy M, Hebbard L. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development. *World J Gastroenterol* 2014; **20**: 16464-16473 [PMID: 25469014 DOI: 10.3748/wjg.v20.i44.16464]

128 **Dapito DH**, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, Caviglia JM, Khiabanian H, Adeyemi A, Bataller R, Lefkowitch JH, Bower M, Friedman R, Sartor RB, Rabadan R, Schwabe RF. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. *Cancer Cell* 2012; **21**: 504-516 [PMID: 22516259 DOI: 10.1016/j.ccr.2012.02.007]

129 **Yoshimoto S**, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, Iwakura Y, Oshima K, Morita H, Hattori M, Honda K, Ishikawa Y, Hara E, Ohtani N. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. *Nature* 2013; **499**: 97-101 [PMID: 23803760 DOI: 10.1038/nature12347]

130 **Kitazawa S**, Denda A, Tsutsumi M, Tsujiuchi T, Hasegawa K, Tamura K, Maruyama H, Konishi Y. Enhanced preneoplastic liver lesion development under 'selection pressure' conditions after administration of deoxycholic or lithocholic acid in the initiation phase in rats. *Carcinogenesis* 1990; **11**: 1323-1328 [PMID: 1974829]

131 **Payne CM**, Weber C, Crowley-Skillicorn C, Dvorak K, Bernstein H, Bernstein C, Holubec H, Dvorakova B, Garewal H. Deoxycholate induces mitochondrial oxidative stress and activates NF-kappaB through multiple mechanisms in HCT-116 colon epithelial cells. *Carcinogenesis* 2007; **28**: 215-222 [PMID: 16887864 DOI: 10.1093/carcin/bgl139]

132 **Kuilman T**, Peeper DS. Senescence-messaging secretome: SMS-ing cellular stress. *Nat Rev Cancer* 2009; **9**: 81-94 [PMID: 19132009 DOI: 10.1038/nrc2560]

133 **Coppé JP**, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. *PLoS Biol* 2008; **6**: 2853-2868 [PMID: 19053174 DOI: 10.1371/journal.pbio.0060301]

134 **Degirolamo C**, Rainaldi S, Bovenga F, Murzilli S, Moschetta A. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. *Cell Rep* 2014; **7**: 12-18 [PMID: 24656817 DOI: 10.1016/j.celrep.2014.02.032]

135 **Ridlon JM**, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. *J Lipid Res* 2006; **47**: 241-259 [PMID: 16299351 DOI: 10.1194/jlr.R500013-JLR200]

136 **Li D**, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. *Lancet* 2004; **363**: 1049-1057 [PMID: 15051286 DOI: 10.1016/S0140-6736(04)15841-8]

137 **Hujoel PP**, Drangsholt M, Spiekerman C, Weiss NS. An exploration of the periodontitis-cancer association. *Ann Epidemiol* 2003; **13**: 312-316 [PMID: 12821269]

138 **Michaud DS**, Joshipura K, Giovannucci E, Fuchs CS. A prospective study of periodontal disease and pancreatic cancer in US male health professionals. *J Natl Cancer Inst* 2007; **99**: 171-175 [PMID: 17228001 DOI: 10.1093/jnci/djk021]

139 **Stolzenberg-Solomon RZ**, Dodd KW, Blaser MJ, Virtamo J, Taylor PR, Albanes D. Tooth loss, pancreatic cancer, and Helicobacter pylori. *Am J Clin Nutr* 2003; **78**: 176-181 [PMID: 12816788]

140 **Farrell JJ**, Zhang L, Zhou H, Chia D, Elashoff D, Akin D, Paster BJ, Joshipura K, Wong DT. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. *Gut* 2012; **61**: 582-588 [PMID: 21994333 DOI: 10.1136/gutjnl-2011-300784]

141 **Mitsuhashi K**, Nosho K, Sukawa Y, Matsunaga Y, Ito M, Kurihara H, Kanno S, Igarashi H, Naito T, Adachi Y, Tachibana M, Tanuma T, Maguchi H, Shinohara T, Hasegawa T, Imamura M, Kimura Y, Hirata K, Maruyama R, Suzuki H, Imai K, Yamamoto H, Shinomura Y. Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. *Oncotarget* 2015; **6**: 7209-7220 [PMID: 25797243]

142 **Shahani L**, Khardori N. Fusobacterium necrophorum--beyond Lemierres syndrome. *BMJ Case Rep* 2011; **2011**: [PMID: 22674593 DOI: 10.1136/bcr.07.2011.4527]

143 **Flanagan L**, Schmid J, Ebert M, Soucek P, Kunicka T, Liska V, Bruha J, Neary P, Dezeeuw N, Tommasino M, Jenab M, Prehn JH, Hughes DJ. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. *Eur J Clin Microbiol Infect Dis* 2014; **33**: 1381-1390 [PMID: 24599709 DOI: 10.1007/s10096-014-2081-3]

144 **Moore PS**, Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. *Nat Rev Cancer* 2010; **10**: 878-889 [PMID: 21102637 DOI: 10.1038/nrc2961]

145 **Lofgren JL**, Whary MT, Ge Z, Muthupalani S, Taylor NS, Mobley M, Potter A, Varro A, Eibach D, Suerbaum S, Wang TC, Fox JG. Lack of commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. *Gastroenterology* 2011; **140**: 210-220 [PMID: 20950613 DOI: 10.1053/j.gastro.2010.09.048]

146 **Peek RM**, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. *Nat Rev Cancer* 2002; **2**: 28-37 [PMID: 11902583 DOI: 10.1038/nrc703]

147 **Hörmannsperger G**, Clavel T, Haller D. Gut matters: microbe-host interactions in allergic diseases. *J Allergy Clin Immunol* 2012; **129**: 1452-1459 [PMID: 22322009 DOI: 10.1016/j.jaci.2011.12.993]

148 [**Levkovich T**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Levkovich%20T%5BAuthor%5D&cauthor=true&cauthor_uid=25722756), [Poutahidis T](http://www.ncbi.nlm.nih.gov/pubmed/?term=Poutahidis%20T%5BAuthor%5D&cauthor=true&cauthor_uid=25722756), [Cappelle K](http://www.ncbi.nlm.nih.gov/pubmed/?term=Cappelle%20K%5BAuthor%5D&cauthor=true&cauthor_uid=25722756), [Smith MB](http://www.ncbi.nlm.nih.gov/pubmed/?term=Smith%20MB%5BAuthor%5D&cauthor=true&cauthor_uid=25722756), [Perrotta A](http://www.ncbi.nlm.nih.gov/pubmed/?term=Perrotta%20A%5BAuthor%5D&cauthor=true&cauthor_uid=25722756), [Alm EJ](http://www.ncbi.nlm.nih.gov/pubmed/?term=Alm%20EJ%5BAuthor%5D&cauthor=true&cauthor_uid=25722756), [Erdman SE](http://www.ncbi.nlm.nih.gov/pubmed/?term=Erdman%20SE%5BAuthor%5D&cauthor=true&cauthor_uid=25722756). 'Hygienic' lymphocytes convey increased cancer risk. *J Anal Oncol* 2014; **3**: 113-121 [PMID: 25722756 DOI: 10.6000/1927-7229.2014.03.03.1]

149 **Grice EA**, Segre JA. The skin microbiome. *Nat Rev Microbiol* 2011; **9**: 244-253 [PMID: 21407241 DOI: 10.1038/nrmicro2537]

150 **Pfirschke C**, Garris C, Pittet MJ. Common TLR5 mutations control cancer progression. *Cancer Cell* 2015; **27**: 1-3 [PMID: 25584886 DOI: 10.1016/j.ccell.2014.12.008]

**P-Reviewer:** Ali I, Banys-Paluchowski M, Vetvicka V **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Table 1 The role of the microbiota in non-gastric cancers**

|  |  |  |
| --- | --- | --- |
| Cancer | Mechanism | Citation |
| Protective role |  |  |
| B16/F10 melanoma and LLC | Microbiota was required for the development of anti-cancer immunityCommensal microbiota was essential for the development and anti-cancer activity of γδ-Th17 cells | [87] |
| HCC | Microbiota was required for immune system developmentCommensal microbiota was needed for the development of the immune system in the liver, which enables mice to clear HBV. A chronic infection with HBV is a major risk factor for HCC | [111] |
| Tumor-promoting role |  |  |
| Skin cancer | Dysbiosis causes a cancer-stimulating inflammatory response in the hostMicrobiota-derived Flagellin stimulates TLR5-MyD88 signaling which promotes skin cancer development | [27] |
| Breast cancer | Upon injection of a carcinogen, GF mice showed a lower cancer burden than SPF mice | [43] |
| Lung  | Dysbiosis causes a cancer-stimulating inflammatory response in the host*E. coli*/LPS in the lungs promotes lung injury and inflammation, which lead to an enhanced metastasis from the primary tumor to the lung | [102] |
| Ovarian and breast cancer | Dysbiosis inhibits anti-tumor immunity:Gut microbiota of TLR5-/- mice promoted the accumulation of MDSCs at the site of breast and ovarian cancers. MDSCs in their turn suppressed anti-cancer immunity | [44] |
| Breast cancer | Infection with a gastric pathogen promoted cancer-stimulating inflammatory responsesIn mice, infection with the gastric bacteria *H. hepaticus* led to an influx of neutrophils in the mammary gland that then promoted cancer. Treatment with antibiotics or the depletion of neutrophils significantly halted cancer development | [30] |
| Liver | Infection of mice prone to liver cancer with *H. hepaticus* led to a significant enhancement of carcinogenesis | [114] |

LLC: Lewis lung carcinoma; HCC: Hepatocellular carcinoma; HBV: Hepatitis B virus; TLR: Toll-like receptor.